Medications

Ozempic vs Wegovy vs Zepbound Compared

Ozempic, Wegovy, and Zepbound compared for Medicare seniors: ingredients, dosing, weight loss vs diabetes, coverage, side effects, and which one to ask about.

Last updated: May 30, 2026

Why the Comparison Matters for Medicare Seniors

If you are a senior on Medicare exploring GLP-1 medications, you have almost certainly heard the names Ozempic, Wegovy, and Zepbound. You may also have heard Mounjaro. These are all GLP-1 receptor agonists, but they are not interchangeable — and Medicare covers them very differently depending on why your doctor prescribes them. Choosing the wrong name when you talk to your doctor can mean the difference between a $50 monthly copay and paying $1,000+ out of pocket.

This guide compares the three head to head: what they are, how they differ, what Medicare covers, and which one to ask your doctor about based on your situation.

The Basics: What Each Drug Is

Ozempic (semaglutide — for diabetes)

Manufacturer: Novo Nordisk
Active ingredient: Semaglutide
FDA-approved for: Type 2 diabetes
How it is taken: Weekly subcutaneous injection
Doses: 0.25mg, 0.5mg, 1mg, 2mg
Medicare coverage: Standard Part D (for diabetes only)

Ozempic was the first of these medications most people heard about. It became famous because patients lost significant weight as a side effect of their diabetes treatment. But its FDA approval is for diabetes, not weight loss — and that distinction is everything for Medicare coverage.

Wegovy (semaglutide — for weight loss)

Manufacturer: Novo Nordisk (same company as Ozempic)
Active ingredient: Semaglutide (same ingredient as Ozempic)
FDA-approved for: Chronic weight management in adults with obesity or overweight with a weight-related condition
How it is taken: Weekly subcutaneous injection
Doses: 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg (higher max dose than Ozempic)
Medicare coverage: GLP-1 Bridge program — flat $50/month (July 2026 through December 2027)

Wegovy is essentially Ozempic's higher-dose sibling, approved specifically for weight loss. The active ingredient is identical — semaglutide — but the maximum dose is higher (2.4mg vs 2mg) and the FDA indication is different. This is the semaglutide product that qualifies for Medicare's $50 Bridge copay when prescribed for weight management.

Zepbound (tirzepatide — for weight loss)

Manufacturer: Eli Lilly
Active ingredient: Tirzepatide (a dual GIP/GLP-1 receptor agonist)
FDA-approved for: Chronic weight management in adults with obesity or overweight with a weight-related condition
How it is taken: Weekly subcutaneous injection
Doses: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg
Medicare coverage: GLP-1 Bridge program — flat $50/month (July 2026 through December 2027)

Zepbound is tirzepatide — a newer, different molecule that works on two receptors instead of one (GIP and GLP-1). Its diabetes counterpart is Mounjaro. In clinical trials, tirzepatide produced somewhat greater average weight loss than semaglutide, though individual results vary widely. Zepbound also qualifies for the $50 Bridge copay.

Quick note on Mounjaro

Mounjaro is the diabetes version of Zepbound, just as Ozempic is the diabetes version of Wegovy. Mounjaro contains the same tirzepatide as Zepbound, is FDA-approved for type 2 diabetes, and is covered under standard Part D for diabetes — not the Bridge.

Head-to-Head Comparison

Feature	Ozempic	Wegovy	Zepbound
Active ingredient	Semaglutide	Semaglutide	Tirzepatide
FDA indication	Type 2 diabetes	Weight management	Weight management
Max weekly dose	2mg	2.4mg	15mg
Avg. weight loss (trials)	10–15%	15–17%	18–22%
Medicare Bridge eligible	No	Yes ($50/mo)	Yes ($50/mo)
Standard Part D	Yes (diabetes)	No	No
Injection frequency	Weekly	Weekly	Weekly
Manufacturer	Novo Nordisk	Novo Nordisk	Eli Lilly

Medicare Coverage: The Critical Difference

This is where most confusion happens, so let us be very clear:

For weight loss on the GLP-1 Bridge ($50/month):

✅ Wegovy — covered
✅ Zepbound — covered
❌ Ozempic — NOT covered (wrong FDA indication)
❌ Mounjaro — NOT covered (wrong FDA indication)

For type 2 diabetes on standard Part D:

✅ Ozempic — covered
✅ Mounjaro — covered
❌ Wegovy — not typically covered for diabetes
❌ Zepbound — not typically covered for diabetes

The drug your doctor prescribes must match the FDA indication. If you want the $50 Bridge price for weight loss, you need Wegovy or Zepbound — not Ozempic or Mounjaro, even though the active ingredients are the same.

Read our full Medicare & GLP-1 coverage guide for details on the Bridge program, eligibility tiers, and prior authorization.

Side Effects Compared

Both semaglutide and tirzepatide cause similar gastrointestinal side effects. The differences are modest:

Semaglutide (Ozempic / Wegovy):

Nausea: ~30–40%
Constipation: ~15%
Diarrhea: ~10%
Generally well-established safety profile (on the market since 2017)

Tirzepatide (Zepbound / Mounjaro):

Nausea: ~25–35%
Constipation: ~10%
Diarrhea: ~15–20% (somewhat more common than with semaglutide)
Newer medication (approved 2022), so long-term data is still accumulating

For a complete breakdown of what to watch for, see our GLP-1 Side Effects in Seniors guide.

Which One Should You Ask Your Doctor About?

The answer depends entirely on your medical situation:

If you have type 2 diabetes and want to manage blood sugar (with weight loss as a bonus): Ask about Ozempic or Mounjaro. These are covered under your regular Part D benefit for diabetes. Weight loss will happen as a side effect — you do not need the Bridge.

If your primary goal is weight loss and you qualify for the Medicare GLP-1 Bridge: Ask about Wegovy or Zepbound. Both are covered at $50/month under the Bridge. Your doctor will help you choose based on your medical history and tolerance.

If you are unsure whether you qualify: Take our free 2-minute Medicare eligibility quiz. It walks you through the BMI tiers, checks for qualifying conditions, and gives you a plain-English read on your Bridge eligibility.

If you have already been using Ozempic off-label for weight loss: Talk to your doctor about switching to Wegovy. It contains the same semaglutide, and the Bridge's $50 price is almost certainly cheaper than what you have been paying.

A Note About Cost Without the Bridge

If you do not qualify for the Bridge and do not have diabetes, these medications are expensive without insurance:

Ozempic: ~$900–$1,000/month
Wegovy: ~$1,300–$1,400/month
Zepbound: ~$1,000–$1,100/month

This is why the Bridge program matters so much for eligible Medicare seniors — it turns a $1,000+ monthly expense into a flat $50. See our Medicare coverage guide for the full eligibility criteria.

Find a GLP-1 Prescriber

If you are ready to discuss GLP-1 options with a doctor, use our Provider Directory to find Medicare-friendly GLP-1 prescribers in your area — searchable by state, city, or ZIP code.

Track Your Progress

Already on a GLP-1? Use the free CairnSpace tracker to log your daily protein, hydration, symptoms, and weight — built specifically for people on GLP-1 medications. No sign-up fees, no ads.

Frequently asked questions

What is the difference between Ozempic and Wegovy?

Both contain the same active ingredient, semaglutide, made by Novo Nordisk. Ozempic is FDA-approved for type 2 diabetes at doses up to 2mg. Wegovy is approved for weight management at a higher max dose of 2.4mg. Medicare covers Ozempic for diabetes under Part D and Wegovy for weight loss under the GLP-1 Bridge at $50 per month.

Is Zepbound better than Wegovy for weight loss?

In clinical trials, tirzepatide (Zepbound) produced somewhat greater average weight loss than semaglutide (Wegovy) — roughly 18 to 22 percent vs 15 to 17 percent of body weight. However, individual results vary widely. Both are covered at the same $50 per month under Medicare's GLP-1 Bridge. Your doctor will help choose based on your medical history.

Does Medicare cover Ozempic for weight loss?

No. Medicare Part D covers Ozempic only when prescribed for type 2 diabetes. For weight loss, the covered drugs under the GLP-1 Bridge are Wegovy and Zepbound, each at a flat $50 per month for eligible seniors. If you want Medicare-covered weight loss, ask your doctor about switching to Wegovy.

What is the difference between Zepbound and Mounjaro?

Zepbound and Mounjaro both contain tirzepatide made by Eli Lilly. Mounjaro is FDA-approved for type 2 diabetes and is covered under standard Medicare Part D. Zepbound is approved for weight management and qualifies for the $50 GLP-1 Bridge. Same drug, different indications and coverage paths.

Can I switch from Ozempic to Wegovy on Medicare?

Yes — discuss this with your doctor. Since both contain semaglutide, switching is straightforward. Wegovy qualifies for the $50 per month GLP-1 Bridge for weight loss, which is almost certainly cheaper than what you are paying for off-label Ozempic use. Your doctor will manage the dose transition.

Wegovy Pill vs Injection: What Medicare Covers →

Wegovy now comes as both a weekly injection and a daily oral tablet. Here's how they compare, what Medicare's GLP-1 Bridge covers, and which to ask about.

What Happens When You Stop a GLP-1? →

Weight regain, appetite return, and side effects when stopping Ozempic, Wegovy, or Zepbound — plus how seniors can taper safely with a doctor on Medicare.

GLP-1 Side Effects in Seniors →

A plain-English guide to the GLP-1 side effects that matter most for seniors — nausea, constipation, muscle loss, fatigue — and when to call your doctor.

Put it into practice

Check your coverage, find a prescriber, and plan your meals — all free.

Eligibility quiz →Find a provider →Meal planner →

← Back to all articles

GLP1 Almanac is an independent reference site. Articles are educational and are not medical advice. Always verify coverage details with your plan or Medicare.gov, and consult your doctor about your care.